The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | BTK degradation shows promise in heavily pretreated CLL
Dima El-Sharkawi, MB, BS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, discusses emerging data from the DAYBREAK CLL-201 trial (NCT07221500) on BTK degraders in heavily pretreated chronic lymphocytic leukemia (CLL). She highlights encouraging responses and manageable toxicity with bexobrutideg, including in patients previously exposed or refractory to both BTK and BCL2 inhibitors, and considers the potential of BTK degradation to address an important unmet need in CLL. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So BTK degraders are a promising new class of drugs. We’ve got Bexarotene as well as other BTK degraders that are showing excellent response rates even in those patients that are not only double exposed, so they’ve already had a BCL2 inhibitor and BTK inhibitor, but often are also double refractory. So they are refractory to both classes of agents. And we are still seeing excellent responses...
So BTK degraders are a promising new class of drugs. We’ve got Bexarotene as well as other BTK degraders that are showing excellent response rates even in those patients that are not only double exposed, so they’ve already had a BCL2 inhibitor and BTK inhibitor, but often are also double refractory. So they are refractory to both classes of agents. And we are still seeing excellent responses. The toxicity profile is similar to what we see with other agents that target BTK as well. So we see cytopenias, infection and contusion and bruising, but they are manageable side effects. And not only are we seeing excellent responses, we’re seeing very durable responses. So I think they are really promising, really exciting. And definitely in that post-BTKI BCL2 cohort of patients will be really game-changing and it’ll be interesting to see as trials develop further forward how our treatment sequencing changes with this new class of agents.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
